Chaibunruang Attawut, Karnpean Rossarin, Fucharoen Goonnapa, Fucharoen Supan
Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand.
Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand; College of Medicine and Public Health, Ubon Ratchathani University, Ubon Ratchathani, Thailand.
Blood Cells Mol Dis. 2014 Apr;52(4):176-80. doi: 10.1016/j.bcmd.2013.11.006. Epub 2013 Dec 5.
AEBart's disease is a thalassemia intermedia usually characterized by the interaction of α(0)-thalassemia with either deletional or non-deletional α(+)-thalassemia in Hb E heterozygote. Genotypic and phenotypic features are heterogeneous. We studied the hematologic and molecular characteristics of this disease in a cohort of 173 Thai patients encountered at our center in northeast Thailand. Hemoglobin and DNA analyses identified patients with deletional AEBart's disease (n=84), Hb Constant Spring AEBart's disease (n=81), Hb Paksé-AEBart's disease (n=5), AEBart's disease with codon 30 mutation (n=1) and two hitherto un-described forms of AEBart's disease due to interaction of Hb E heterozygote and α(0)-thalassemia with the -α(16.6)kb deletional α(+)-thalassemia (n=1) and Hb Q-Thailand (n=1). Different phenotypic expression of these AEBart's diseases with low Hb, Hct and MCV and increased RDW values with marked reduction in Hb E levels were observed. It was found that all these forms of AEBart's disease showed similar thalassemia intermedia phenotypes but those with non-deletional forms were relatively more anemic. Our data confirm that in such area with high prevalence of hemoglobinopathies such as Southeast Asia, identification of rare thalassemia alleles in a thalassemia intermedia patient should not be ignored. Careful consideration of different phenotypic expression may help in providing presumptive diagnosis of this disease where access to molecular testing is limited. However, molecular diagnostic is useful for predicting the clinical outcome and improving genetic counseling of these complex hemoglobinopathies.
血红蛋白E巴特氏病是一种中间型地中海贫血,通常表现为α(0)地中海贫血与血红蛋白E杂合子中缺失型或非缺失型α(+)地中海贫血相互作用的结果。其基因型和表型特征具有异质性。我们研究了泰国东北部我们中心收治的173例泰国患者中这种疾病的血液学和分子特征。血红蛋白和DNA分析确定了缺失型血红蛋白E巴特氏病患者(n = 84)、血红蛋白恒河猴血红蛋白E巴特氏病患者(n = 81)、巴色血红蛋白E巴特氏病患者(n = 5)、密码子30突变的血红蛋白E巴特氏病患者(n = 1)以及两种迄今未描述的血红蛋白E巴特氏病形式,分别是由于血红蛋白E杂合子与α(0)地中海贫血和-α(16.6)kb缺失型α(+)地中海贫血相互作用导致的(n = 1)以及血红蛋白Q - 泰国型(n = 1)。观察到这些血红蛋白E巴特氏病具有不同的表型表达,表现为血红蛋白、血细胞比容和平均红细胞体积降低,红细胞分布宽度值增加,且血红蛋白E水平显著降低。研究发现,所有这些形式的血红蛋白E巴特氏病都表现出相似的中间型地中海贫血表型,但非缺失型的贫血相对更严重。我们的数据证实,在东南亚这种血红蛋白病高发地区,对于中间型地中海贫血患者中罕见的地中海贫血等位基因的鉴定不容忽视。仔细考虑不同的表型表达可能有助于在分子检测受限的情况下对这种疾病进行初步诊断。然而,分子诊断对于预测这些复杂血红蛋白病的临床结局和改善遗传咨询是有用的。